Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B10 | O60218 | 6/20 | 1.00 |
| ▸ | AKR1B1 | P15121 | 6/20 | 1.00 |
| ▸ | CA12 | O43570 | 6/20 | 1.00 |
| ▸ | CA7 | P43166 | 6/20 | 1.00 |
| ▸ | CA9 | Q16790 | 6/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 6/20 | 1.00 |
| ▸ | CA4 | P22748 | 4/20 | 1.00 |
| ▸ | CA6 | P23280 | 4/20 | 1.00 |
| ▸ | CA5A | P35218 | 4/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | MAOB | P27338 | 1/20 | 0.76 |
| ▸ | TTR | P02766 | 1/20 | 0.74 |
| ▸ | CA1 | P00915 | 4/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | MET | P08581 | 2/20 | 0.63 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501585 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL15419990 | 1.00 | AKR1B10 (1.00) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL13552179 | 0.95 | LMNA (0.93) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL22510990 | 0.94 | AKR1B10 (0.88) | AKR1B10AKR1B1CA12CA7CA9 | |
| Benzyl Cinnamate SCHEMBL43212 | 0.92 | LMNA (1.00) | AKR1B10AKR1B1CA12CA7CA9 | |
| Benzyl Cinnamate SCHEMBL1871854 | 0.92 | LMNA (1.00) | AKR1B10AKR1B1CA12CA7CA9 | |
| Benzyl Cinnamate SCHEMBL43213 | 0.92 | LMNA (1.00) | AKR1B10AKR1B1CA12CA7CA9 | |
| Benzyl Cinnamate SCHEMBL901152 | 0.92 | LMNA (1.00) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL22071063 | 0.90 | LMNA (0.84) | AKR1B10AKR1B1CA12CA7CA9 | |
| SCHEMBL29641956 | 0.89 | LMNA (0.82) | AKR1B10AKR1B1CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638648-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN INC. (US) | 2009-12-29 | — | — | US | disclosed |
| US-7468391-B2 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7226951-B2 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| EP-1699775-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | Allergan, Inc. (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1696899-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | ALLERGAN, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | ALLERGAN, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2005058798-A2 | COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058301-A1 | METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B | ALLERGAN, INC. (US) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176689-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | AKR1B10 141/4885AKR1B1 99/4885CA12 3105/4885 |
| US-20050187298-A1 | Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B | CYP26B1, CYP2A6, CYP21A2 | AKR1B10 55/4885AKR1B1 24/4885CA12 2544/4885 |
| US-20080004455-A1 | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same | CYP1A2, CYP2A7, CYP3A7 | AKR1B10 141/4885AKR1B1 99/4885CA12 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.